December 16, 2014
ViiV Healthcare K.K. filed a new drug application (NDA) on December 15 for its triple fixed-dose combination tablet for HIV treatment containing its integrase inhibitor Tivicay Tablets (dolutegravir), which was launched in Japan April, and two nucleoside reverse transcriptase inhibitors...read more